Posted on

Awakn Life Sciences to Participate at Upcoming March 2022 Conferences

Awakn Life Sciences to Participate at Upcoming March 2022 Conferences

TORONTO, CANADA, March 09, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction, announced today that Anthony Tennyson, Chief Executive Officer, is scheduled to present at the following upcoming March 2022 investor conferences. 

34th Annual ROTH Conference

Presentation: Sunday, March 13th to Tuesday, Match 15th 

Registration: Click here 

Oppenheimer’s 32nd Annual Healthcare Conference

Presentation: Wednesday, March 15th to Thursday, March 17th 

Registration: Please contact your Oppenheimer representation 

Maxim’s 2022 Virtual Growth Conference 

Presentation: Monday, March 28th to Wednesday, March 30th 

Registration: Click here

For more information about each conference, or to schedule a one-on-one meeting with Awakn’s management team, please contact your ROTH, Oppenheimer or Maxim representatives, or alternatively KCSA Strategic Communications at Awakn@kcsa.com.  

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction. Awakn’s team consists of renowned research experts and world leading chemists, scientists, psychiatrists, and psychologists. Addiction is one of the biggest unmet medical needs of our time, affecting over 20% of the global population and is an industry valued at over $100bn per annum. Awakn is disrupting this underperforming industry by rapidly advancing the next generation of psychedelic drugs and therapies to be used in combination, through preclinical research and clinical stage trials.

www.awaknlifesciences.com  |  Twitter  |  LinkedIn  |  Facebook

Investor Enquiries:
KCSA Strategic Communications 
Valter Pinto / Tim Regan 
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:

America and Canada: KCSA Strategic Communications  
Anne Donohoe 
Adonohoe@KCSA.com

Rest of World: ROAD Communications 
Paul Jarman / Nora Popova
Awakn@roadcommunications.co.uk

Posted on

Awakn Files Patent For A New Class Of Entactogen-Like Molecules

Awakn Files Patent For A New Class Of Entactogen-Like Molecules

Entactogen NCE series enhances the potential to treat a broad range of addictions

TORONTO, CANADA, FEBRUARY 17, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, strengthened its intellectual property portfolio and pipeline for the treatment of addictions with the filing of a patent application for a new chemical series of entactogen-like molecules. Entactogen-like molecules are a class of psychoactive substances that produce distinctive emotional and social effects that Awakn believes has great potential to treat both substance and behavioural addictions.

Awakn’s latest patent application, which covers the new chemical series, fulfils another significant step forward in the development of next generation entactogens and provides a key milestone in Awakn’s drug discovery program. The application further strengthens Awakn’s pipeline and position as a global leader in the psychedelic-biotechnology industry.

Professor David Nutt, Chief Research Officer at Awakn, commented, “The novel entactogen-like molecules being developed at Awakn and protected in this patent, build on our recent filings to establish a strong pipeline of Novel Chemical Entities. These molecules have the potential to revolutionize the treatment of addiction by delivering improved efficacy in a shorter treatment time. Our aim is to treat addiction patients, more rapidly, effectively, and safely than has been possible to date.” 

Awakn and its research partner, Evotec, have used an Artificial Intelligence approach to identify initial hits. A number of these hits were verified using a set of in vitro screening and ADMET assays leading to the identification of multiple patentable series. 

Anthony Tennyson, Awakn’s CEO commented, “We are delighted with the pioneering progress we have made, and it is a testament to our world class team to have achieved another significant milestone in our drug discovery program. Increasing efficacy, while being able to deliver that in a shorter time frame, is what every biotech in this space is trying to do. We believe we have taken a big step in that direction with this patent application.”

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are advancing the next generation of psychedelic drugs and therapies to be used in combination.

www.awaknlifesciences.com  |  Twitter  |  LinkedIn  |  Facebook

Notice Regarding Forward Looking Information

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company’s future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company’s public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company’s and Awakn’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:
KCSA Strategic Communications 
Valter Pinto / Tim Regan 
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:
America and Canada: KCSA Strategic Communications  
Anne Donohoe 
Adonohoe@KCSA.com

Rest of World: ROAD Communications 
Paul Jarman / Nora Popova
Awakn@roadcommunications.co.uk

Posted on

Awakn Life Sciences’ Professor Celia Morgan Named One Of The Most Influential Women In The Psychedelics Industry

Awakn Life Sciences’ Professor Celia Morgan Named One Of The Most Influential Women In The Psychedelics Industry

Professor Morgan, Awakn’s Head of Ketamine-Assisted Therapy for Addiction, named one of the 16 most influential women shaping the future of psychedelics by Insider

TORONTO, CANADA, 15 February 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announced that Professor Celia Morgan, the Company’s Head of Ketamine-Assisted Therapy for Addiction, was named one of Insider’s 16 most influential women shaping the future of psychedelics.

“We are excited to share this well-deserved recognition for Celia and congratulate her on her pioneering work, which is helping to shape the psychedelic industry. She truly is an industry leader in the field of Ketamine-assisted therapy,” said Anthony Tennyson, Awakn Life Sciences CEO. “Celia’s research showcases that Ketamine-assisted therapy can have a significant, positive impact on the millions of people currently suffering with Addiction and we’re so proud to support her continued work.”

Professor Celia Morgan added, “I am greatly honoured to be showcased amongst these incredible women shaping the future of psychedelics and look forward to all that we can accomplish together to help the millions of people that are suffering from various mental illnesses and behavioural disorders.”

Professor Morgan recently published Phase II A/B trial data in the American Journal of Psychiatry showcasing the efficacy of Ketamine-assisted therapy for the treatment of alcohol use disorder. The findings showed that Ketamine-assisted therapy, resulted in total abstinence in 162 of 180 days in the following 6-month period, achieving an increase in abstinence from around 2% prior to the trial to 86% six-months post trial. 

Professor Morgan is also leading the world’s first ketamine treatment study for gambling addiction, which was previously announced in August 2021. This research is the first such study to look at psychedelics for the treatment of a behavioural addiction. The study was also approved last month to expand to other behavioural addictions such as Binge Eating Disorder, Compulsive Sexual Behavior and Internet Gaming Disorder. 

Morgan’s work has been supported with more than $8 million in grant funding from the UK government and beyond. 

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are advancing the next generation of psychedelic drugs and therapies to be used in combination.

www.awaknlifesciences.com  |  Twitter  |  LinkedIn  |  Facebook

Investor Enquiries:
KCSA Strategic Communications 
Valter Pinto / Tim Regan 
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:
America and Canada: KCSA Strategic Communications  
Anne Donohoe 
Adonohoe@KCSA.com
Rest of World: ROAD Communications 

Paul Jarman / Nora Popova

Awakn@roadcommunications.co.uk

Posted on

Awakn Life Sciences to Host Fireside Chat with Dr. Ben Sessa, Chief Medical Officer, on March 2nd at 11:00am EST

Awakn Life Sciences to Host Fireside Chat with Dr. Ben Sessa, Chief Medical Officer, on March 2nd at 11:00am EST

Dr. Sessa Will Discuss the Promise of Psychedelic Medicine in Treating Addiction

Toronto, Ontario–(Newsfile Corp. – February 10, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, will host a fireside chat with Dr. Ben Sessa, Chief Medical Officer, on Wednesday, March 2nd at 11:00 a.m. EST. Dr. Sessa, author of ‘The Psychedelic Renaissance’ amongst other titles, is renowned as one of the most influential figures in the psychedelic industry, having spent the last 15 years at its forefront. He also led the world’s first MDMA -assisted therapy clinical trial for the treatment of Alcohol Use Disorder.

During the video webinar, Dr. Sessa will discuss the psychedelic industry landscape and Awakn’s unique and differentiated approach to advancing psychedelic therapeutics to treat Addiction. Additionally, he will review some of the Company’s anticipated milestones for 2022 and discuss the Company’s plan to execute on its vision to researching, developing, and delivering psychedelic therapeutics as more than an alternative treatment option.

The webinar is open to the public. Participants will have an opportunity to ask questions during the Q & A portion of the webinar.

To register for the event please visit here.

For additional information, please contact KCSA Strategic Communications by emailing Awakn@kcsa.com.

Further to its press release dated November 30, 2021, the Company is pleased to announce the appointment of Katherine Butler as Chief Financial Officer of the Company, and the appointment of Jonathan Held as Chief Business Officer of the Company, will be effective as of February 14, 2022.

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are advancing the next generation of psychedelic drugs and therapies to be used in combination.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
Adonohoe@KCSA.com

Rest of World: ROAD Communications
Paul Jarman / Nora Popova
Awakn@roadcommunications.co.uk

Posted on

Swimming in acid to cure rare diseases: issue 35

Hello and welcome back.

We loved connecting with you all at the Daily Mushroom + Entheon Biomedical Mental Health Town Hall last night 😍 If you couldn’t make it, no worries, we got you. Check out the recording below.

Here’s what’s in store for you in today’s issue:

🍄 A cure for the most annoying Covid symptom?

🍄 Reducing suicidality for 6 months

🍄 Microdosing for withdrawals

🍄 How to prevent bad trips

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Mental Health Townhall

On this very special episode of the Daily Mushroom Podcast, we were lucky enough to be joined by some pretty amazing guests. We had Andy Greenshaw, David Mayoh, Timmothy Ko, Valorie Masuda, Marsha Bennett, and of course our host Brett Higson. We asked our readers to submit questions they had about psychedelics for our knowledgeable board to answer and they did not disappoint! This episode is full of all kinds of insight into the expanding world of psychedelic therapy and what the future may hold.

Therapeutic banner

Swimming in acid 🐠

New research suggests that microdosing doesn’t cause withdrawal symptoms. But can it ease withdrawals from other substances?

MacEwan University researchers found that zebrafish showed increased anxiety behaviour during withdrawal from alcohol, consistent with symptoms that humans experience.  

However, when the zebrafish were given microdoses of LSD for 10 days (by putting them in a “dosing tank” for a precise period of time), there were no observed behavioural changes. This indicates that microdosing is not addictive and does not cause withdrawal symptoms. 

A study that’s currently underway will examine LSD microdoses on alcohol withdrawal symptoms.

Did you know we share 70% of our genes with zebrafish? Plus, they are extremely social, making them ideal for behavioural studies. 

Treating rare disorders with ketamine

PharmaTher (PHRM) is developing a treatment for a rare, seizure-inducing disorder called Status Epilepticus using ketamine. This week, it was granted a designation that will save them millions of dollars in the process. 

It’s called an Orphan Drug Designation and it gives the company potential tax credits, grant eligibility, and marketing exclusivity, and waives a $2.4M New Drug Application fee. It’s designed to incentivize R&D of treatments for rare conditions.

PharmaTher previously received the designation for ketamine to treat ALS and complex regional pain syndrome too!

inspirational banner

A cure for the most annoying Covid symptom?

Even months or years after recovering from Covid, many people have no sense of taste or smell – or worse, everything tastes and smells disgusting. 

People are rushing to Reddit and Twitter to share that they’ve finally found a cure: shrooms!

Some report that their senses returned to normal after one dose while others say they were restored gradually over a handful of trips.

Here’s one Reddit user’s experience: “I was shocked and elated.. ran around to find a candle, picked it up, lavender! Began to cry. Began smelling everything in sight. You don’t realize how beautiful it is to smell things, until you can’t smell for almost a year.”

Reducing suicidality for 6 months

A meta-analysis of 7 clinical trials (5 psilocybin + 2 ayahuasca) found that psychedelic therapy significantly reduced suicidality in as little as 80 minutes.

The significant reductions were sustained for 3-4 months, and patients still had a moderate reduction in suicidality after 6 months.

business banner

Entheon Biomedical (ENBI) received approval for a phase I DMT trial and will begin screening patients this month. The trial, which will be conducted in the Netherlands, will gather essential safety and dosing data needed for a phase II study on DMT for nicotine addiction.

Awakn Life Sciences (AWKNF) received a buy rating and a $10 price target from H.C. Wainwright – that’s a 530% increase from its current share price of $1.58 🤑

Lexston Life Sciences (LEXT) received a Section 56 exemption to research psilocybin. It is developing a tool that can rapidly identify and quantify different mushroom compounds such as psilocin, psilocybin, baeocystin, norbaeocystin and aeruginascin.

Tryp Therapeutics (TRYP) announced Q1 financial results including $2.1M in cash and a $3.0M loss for the three months ended November 30, 2021. The company also secured a $2M private placement this week. 

An individual in Oregon was issued a patent for a vape pen for “ayahuasca-like substances” including DMT, 5-MeO-DMT, and 2CB. The decision is receiving backlash from many who claim that the technology is not novel and has been around for years.

How to prevent bad trips

Tripping can be scary. You never really know how hard a dose will hit you or how long the effects will last — especially if it’s your first time.

What if there was a way to get some insight? Well, there is – HaluGen’s Psychedelic Genetic Test.

With a simple cheek swab, the test tells you:

  • How sensitive you are to classical psychedelics like psilocybin, LSD, and DMT
  • How quickly your body metabolizes MDMA, LSD, ayahuasca, and ketamine
  • If your genetics put you at risk of developing psychosis, bipolar disorder, or schizophrenia
  • If you’re prone to adverse reactions from SSRIs

Use the results to find the dose that’s right for you so you can have the best experience possible!

 

Get 10% off when you use promo code ‘dailymushroom’

Buy a test
See a sample of the results
legal banner

The good

  • Oregon legislators filed a bill to form a 15-member task force to ensure that access to legal psilocybin services is equitable for all. It will focus on removing barriers for minorities and people with low income. Read more…
  • A second ballot initiative has been filed in Colorado to decriminalize the possession, cultivation, and gifting of psilocybin, psilocyn, ibogaine, mescaline and DMT. The first measure would create legal psilocybin healing centers. Read more…
  • A ballot measure was filed in Michigan to legalize possession, cultivation, and sharing of a range of psychedelics and implement a system for therapeutic and spiritual use. Read more…

The bad

  • A measure that would have decriminalized therapeutic psilocybin in Virginia was defeated by the Senate Judiciary Committee. The bill’s sponsor plans to bring the bill back next year. Read more…
  • Washington’s initiative to legalize guided psilocybin sessions will not pass, according to the bill’s sponsor, Sen. Jesse Salomon. He explains that there are concerns of facilities losing federal revenue for offering the services, and that the Department of Health is too busy with Covid to implement new regulatory framework. Read more…
  • A lawsuit filed by a physician and his cancer patients against the DEA for denying access to psilocybin therapy was rejected by the Court of Appeals. Read more…

And the ugly

  • Health Canada denied dozens of healthcare practitioners access to psilocybin therapy training by rejecting their section 56 exemption applications. Now, clinical trials will likely be the only way to get experience with the psychedelic. TheraPsil, the non-profit that helped with the applications, says that this will impact over one thousand practitioners on their waitlist for psilocybin training and several thousand patients seeking care 💔 Read more…

Video of the Week

The Battle Over Psychedelic Therapy’s Future

Playlist of the Week

Trippy Songs 🍄🍃👽🚀
Posted on

Awakn Life Sciences Files Patent Application For A New Class Of Entactogen-Like Molecules To Treat A Broad Range Of Addictions

Awakn Life Sciences Files Patent Application For A New Class Of Entactogen-Like Molecules To Treat A Broad Range Of Addictions

Novel Entactogen NCE series enhances the potential for improved treatment of addiction

TORONTO, CANADA, 26 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announces the filing of a patent application for a new chemical series of entactogen-like molecules, further strengthening Awakn’s intellectual property portfolio and pipeline for the treatment of a broad range of addictions including, but not limited to substance addictions such as Alcohol, and behavioural addictions, such as Gambling Disorder and Compulsive Sexual Behaviour.

The new chemical series patented by Awakn, delivers a significant step forward in the development of entactogens and provides a key milestone in Awakn’s drug discovery R&D activities. Awakn’s innovative pipeline of NCE’s further adds to existing patent applications and active clinical development programmes (KARE: completed phase-IIa/b trial and BIMA: completed phase-IIa trial), strengthens Awakn’s position as a global leader in the psychedelic-biotechnology industry.

Chief Scientific Officer at Awakn, Shaun McNulty commented, “The new chemical series of entactogen-like molecules being developed at Awakn will deliver the best characteristics of existing entactogens, with a shorter duration of action. This can improve clinical utility in a research space and has significant potential for the delivery of the treatments. These improved entactogens will enable us to treat more patients and has the potential to increase the range of disorders we can treat.  This will enable us to make rapid progress towards treating a broad range of addictions, a condition with huge unmet medical needs and significant negative impact on society.”

Awakn announced in October they would progress the NCE program into lead optimization with their research partner Evotec. These novel entactogen-like molecules which the patent has been filed for will be an integral part of this research program, with the aim to develop one or more compounds and progress them into clinical development. 

Anthony Tennyson, Awakn’s CEO commented, “Our ambition is to fully integrate effective psychedelic-based treatment into mainstream healthcare to better treat addiction. We are fortunate to have many of the world’s leading researchers and drug discovery experts supporting and delivering our vision at Awakn. Our clinical team has unparalleled experience in treating addiction, and now with the development of a new entactogen series and a world-class entactogen discovery pipeline, Awakn’s place as a global leader in this space is strengthened.”

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are advancing the next generation of psychedelic drugs and therapies to be used in combination.

Awaknlifesciences.com  |  Twitter  |  LinkedIn  |  Facebook

Notice Regarding Forward Looking Information

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company’s future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company’s public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company’s and Awakn’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:

KCSA Strategic Communications 
Valter Pinto / Tim Regan 
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:

America and Canada: KCSA Strategic Communications  
Anne Donohoe 
Adonohoe@KCSA.com

Rest of World: ROAD Communications 
Paul Jarman / Nora Popova
Awakn@roadcommunications.co.uk

Posted on

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

VANCOUVER, BC, Jan. 25, 2022 – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, today announced its financial results and operational highlights for the three and six months ended November 30, 2021. All amounts are stated in Canadian dollars unless otherwise indicated.  

Fiscal Q2 2022 Business Highlights

  • Commenced trading on the OTCQX Best Market on September 30, 2021, the highest tier of OTC Markets Group, under the ticker symbol “MCURF”.
  • Closed an exclusive data licensing agreement with ATMA Journey Centers Inc., a pioneer in the psychedelic therapy industry, and was granted exclusive access to ATMA data from patients using iSTRYM, the Company’s digital therapeutics technology. The data will be leveraged to further optimize iSTRYM and position it as the industry’s distribution network for science-based, evidence-backed protocols and AI data systems.
  • Signed a letter of intent with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) to be a distributor of its ketamine-assisted psychotherapy for Alcohol Use Disorder protocol in the US and Canada.
  • Partnered with 20 ketamine clinics in nine states in the U.S. and three provinces in Canada to release the minimum viable product version of iSTRYM, with plans to further expand in 2022.
  • Introduced the “Desire Project”, a clinical research program focused on the treatment of female hypoactive sexual desire disorder with MDMA-assisted psychotherapy. This is the first psychedelics-based treatment program targeted at addressing Hypoactive Sexual Desire Disorder.
  • Joined the Digital Therapeutics Alliance, a non-profit association of industry leaders with a mission to drive awareness and adoption of digital therapies.
  • Advanced preparations to ship ibogaine drug material to its pre-clinical research partner.
  • Included in the AdvisorShares Psychedelics ETF, which trades on the NYSE Arca under the ticker symbol “PSIL”.

Recent Events

  • The Company and its digital therapeutics technology, iSTRYM, were certified as Health Insurance Portability and Accountability Act (HIPAA) compliant, making a further step toward commercial deployment in the second quarter of 2022.
  • Appointed Dr. Doron Sagman, MD, FRCPC, as the Company’s new Chief Medical Officer (“CMO”). Dr. Joel Raskin who was acting CMO will transition into an advisory role.

“During the second quarter of fiscal 2022, we achieved several key milestones across our digital technology and research projects, further proving our ability to successfully execute against our strategic growth strategy,” said Kelsey Ramsden, President & CEO of MINDCURE. “We are continuing to build out our team with key industry leaders, positioning the Company to develop innovative treatments that promote healing and improve mental health.”

Financial Highlights

  • Net loss for the three months ended November 30, 2021 was $2.95 million, comprised of cash operating expenses of $2.9 million, non-cash operating expenses of $0.3 million and an unrealized gain of $0.2 million.
  • Cash and cash equivalents totalled $13.4 million as of November 30, 2021.

A copy of the Company’s financial statements for the three and six months ended November 30, 2021 and the related management’s discussion and analysis are available under the Company’s profile on SEDAR at www.sedar.com.

In other news, the Company also announces it has granted a total of 110,000 stock options to certain employees pursuant to the terms the Company’s long term incentive plan (“Plan”). The stock options are exercisable at a price of $0.21 per share, and are subject to the terms of the Plan.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; that MINDCURE will advance wellness worldwide; that iSTRYM will be brought to commercial deployment in the near term or otherwise or that it will reduce symptoms, improve quality of life, or support transformation and healing, or that the deployment may not occur at the scale or within the time frame contemplated.

Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

For further information: MINDCURE Investor Relations, Daniel Kim, VP Investor Relations, dkim@mindcure.com, 1-888-593-8995

Posted on

How hallucinogenic beer shaped history: issue 33

Hello and welcome back.

Thank you to everyone who registered for our Mental Health Town Hall. We can’t wait to connect with you! If you haven’t signed up yet, don’t worry, it’s not too late. Keep reading for details.

Here’s what’s in store for you in today’s issue:

🍄 How psychedelics helped an ancient empire maintain power

🍄 Add some ecstasy to your sex life

🍄 Microdosing DMT

🍄 Australian gov’t funds 2 psychedelic studies

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Healing at home with Nue Life’s innovative ketamine wellness program

In this episode of the Daily Mushroom Podcast, we have Juan Pablo Cappello, co-founder and CEO of Nue Life Health. Nue Life’s at-home ketamine wellness program is proving to be highly beneficial for patients with treatment-resistant depression. The key is in the company’s unique approach to integration, which utilizes intuitive AI, music therapy, and group support. 

Nue Life is a public benefits corporation, and its entire founding team is made up of people of colour and women. Learn how Juan Pablo Cappello used spiritual wisdom to create a conscious business in his talk, 4 Pillars of Conscious Startups.

This will be an inspiring event for anyone who dreams of running a tech startup or wants to bring conscious leadership to their workplace.

Therapeutic banner

Add some ecstasy to your sex life

Over 90% of people experienced increased sexual desire and satisfaction after taking MDMA. But that’s not the only way it can improve your sex life.

Mindcure (MCUR) is studying MDMA-assisted-therapy as a treatment for Hypoactive Sexual Desire Disorder (HSDD), which is characterized by low sex drive and emotional distress. 

The goal is to use MDMA to get to the root cause of the issue, which may be a history of negative sexual experiences and relationships or struggles with self worth or body image.

Microdosing DMT

Algernon Pharmaceuticals (AGN) found that microdoses of DMT can increase the growth of neurons in the brain by up to 40%. An upcoming study will see if this can benefit stroke patients.

Phase I of the study, which is awaiting approval in the UK, will determine the maximum amount of DMT that can be taken without producing a psychedelic effect. Phase II will test repeated doses on acute and recovering stroke patients.

Treating alcoholism in Europe

Last year, Awakn Life Sciences (AWKN) found that MDMA-assisted therapy helped alcoholics reduce alcohol consumption by 85% – from an average of 130.6 units per week to just 18.7.

Now, the company is exploring a partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS) to treat alcohol use disorder across Europe, where alcohol is one of the top five causes of disease and disability in most countries. Awakn may license MAPS’ pre-clinical data to get the treatment to market faster.

Microdosing eases depression

In a preclinical animal model, Wesana Health (WESA) found that a single high dose of psilocybin rapidly improved depressive behaviours for 14 days. A regimen of psilocybin microdoses and CBD was able to sustain the results and reduced depressive behaviours by an additional 64%.

Let’s keep the microdosing evidence coming!

inspirational banner

Be an industry insider

How can DMT be improved to better treat addiction? How do our genetics influence our psychedelic experiences? How does ketamine change our brain wave patterns? Does music make psychedelic therapy more effective?

These are all questions that Entheon Biomedical (ENBI) is answering with ongoing clinical research. Learn what they’ve discovered so far and their next steps at our Mental Health Town Hall this February 3rd!

We’ll be joined by Entheon’s Founder and CEO, Scientific Advisor, and Communications Manager to discuss the company’s findings and the future of psychedelic therapy. Register now for free to get the inside scoop 👇

Save the toads

Did you know that potent psychedelics like 5-MeO-DMT and bufotenin come from the venom of the Colorado River Toad? 

With growing demand to study these compounds and increased recreational use, wild populations of the toad are threatened in some areas.

Alvarius Research Inc. recently developed a toad conservation program to address this issue. The company is also collaborating with Egret Bioscience to develop synthetic “toad-free” versions of the compounds.

Psychedelics → power?

An ancient South American empire called the Wari Empire may have used a hallucinogenic beer to maintain its power.

The Wari people brewed a beer-like drink with seeds from the vilca tree, which contain a psychedelic compound called bufotenin (one of the substances found in toad venom!). 

Archeologists believe that Wari leaders served the drink at feasts to strengthen social connections with guests from surrounding regions. Guests likely had a euphoric or spiritual experience, compelling them to “acknowledge the power of their hosts or feel the need to owe them a favor in the future,” explains one archeology expert. 

Could this be why the empire maintained political control for hundreds of years? 🤔

Connect with your microdosing community

If you’re looking to try microdosing, what better way to get started than with a community of like-minded individuals. 

Dose Day is a microdosing peer support network that connects you with a small group with similar intentions and interests. Meet with your group weekly to see how the power of community can support you on your journey.

Whether you’re an artist, an executive, a consciousness junkie or someone looking to improve their mental health, there is a group for you.

Plus, half the fee supports palliative care patients with end-of-life anxiety.

business banner

Psygen Industries Ltd. is building Canada’s first manufacturing facility dedicated to synthetic psychedelics. The company received authorization to produce and sell psilocybin, psilocin, LSD, DMT, mescaline, and 2C-B through a Health Canada Dealer’s License. It has already established over 20 supply agreements with domestic and international companies 👏

Numinus Wellness (NUMI) is enrolling patients for a multi-site study on MDMA for PTSD, which will be sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). The study received approval from both Health Canada and the Institutional Ethics Review Board.

Eleusis, a UK-based company focused on psilocybin therapy for depression, is planning to go public through a $446M merger with Silver Spike Acquisition Corp. II (SPKB). Eleusis will apply to have its shares listed on the NASDAQ under the symbol ‘ELEU’.

Red Light Holland (TRIP) is collaborating with an advocacy group called the Psychedelic Medicine Alliance Washington to promote a bill that would legalize guided psilocybin sessions in Washington State. The company has hired a lobbyist with experience in cannabis regulation and is launching a social media campaign and educational events to raise awareness about the benefits of psilocybin.

legal banner

Here’s what you missed in the legal world:

  • University of Sydney researchers received $3M in funding from the Australian government to support MDMA and psilocybin studies! The MDMA study will investigate combined PTSD and alcohol use disorder, and the psilocybin study will be focused on anorexia nervosa. Read more…
  • A Kansas legislator filed a bill to legalize the possession of up to 50 grams of psilocybin or psilocin, as well as the cultivation of psilocybin mushrooms. Read more…
  • A Utah Rep. filed a bill that would establish a task force to research the therapeutic potential of psychedelics. Read more…
  • Representatives from seven US states (Oregon, Nebraska, Michigan, Arizona, Texas, Minnesota, and Pennsylvania) have submitted a letter urging the Drug Enforcement Administration (DEA) to allow terminally-ill patients access to psilocybin treatments. The lawmakers believe that psilocybin qualifies as an investigational drug and should therefore be accessible through Right to Try laws. Read more…

Video of the Week

The Battle Over Psychedelic Therapy’s Future

Playlist of the Week

Trippy Songs 🍄🍃👽🚀
Posted on

Treating alcoholism in Europe

Last year, Awakn Life Sciences (AWKN) found that MDMA-assisted therapy helped alcoholics reduce alcohol consumption by 85% – from an average of 130.6 units per week to just 18.7.

Now, the company is exploring a partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS) to treat alcohol use disorder across Europe, where alcohol is one of the top five causes of disease and disability in most countries. Awakn may license MAPS’ pre-clinical data to get the treatment to market faster.

logo

PDF of article

Posted on

Awakn Life Sciences Signs MOU With MAPS

Awakn Life Sciences Signs MOU With MAPS

Agreement to explore a partnership for MDMA-Assisted Therapy for treatment of Alcohol Use Disorder in Europe

TORONTO, CANADA, 19 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today it has signed a Memorandum of Understanding (“MOU”) with the Multidisciplinary Association for Psychedelic Studies (MAPS) to explore a partnership to utilize MDMA-assisted therapy to treat Alcohol Use Disorder (AUD) in Europe. 

Under the terms of this MOU, Awakn will explore a data licensing agreement with MAPS to support Awakn’s Phase IIb and planned Phase III studies for MDMA-assisted therapy for AUD in Europe. Awakn and MAPS will also assess a partnership to secure marketing authorisation/regulatory approval for the ethical commercialization of MDMA-assisted therapy for the treatment of AUD in Europe. 

AUD is a chronic disease affecting 40 million people in Europe and 390 million people globally. It is also a pervasive and persistent public health issue, with alcohol use being one of the top five causes of disease and disability in the majority of countries in Europe. And for each person suffering from AUD, there is a friend, a partner, or a family also deeply affected by it.

In February 2021, Awakn announced the publication of the successful results of the BIMA Phase IIa study investigating MDMA-assisted therapy for the treatment of AUD, reporting a 21% relapse rate at 9 months in comparison to a 75% relapse rate in a separate observational group.

In May 2021, MAPS announced that it achieved successful results in its first of two Phase III trials for MDMA-assisted therapy for the treatment of severe chronic PTSD. In this study, 88% of participants who received three MDMA-assisted therapy sessions – along with twelve 90-minute, non-drug preparation and integration therapy sessions – experienced a clinically meaningful reduction in symptoms. 67% of participants no longer qualified for a PTSD diagnosis.

“MAPS’ role in driving and advancing the use of psychedelics in the clinical setting over the last 35 years is second to none,” said Anthony Tennyson, Awakn’s CEO. “We believe that by licensing MAPS’ pre-clinical data and exploring options for future ethical commercialisation, we will improve the timeline and path to market for these life-changing treatments for AUD, providing hope for those for whom the status quo is not working.” 

“MAPS has been working with AWAKN scientists for decades in the effort to initiate trials into a range of clinical uses of MDMA-assisted therapy,” shares Rick Doblin, Founder and Executive Director of MAPS. “We’re delighted to be entering into this MoU with AWAKN which holds great promise for people suffering from AUD.”

Awakn also recently announced groundbreaking results from its Phase IIa/b ‘Ketamine for the Reduction of Alcoholic Relapse’ (KARE) clinical trial. It was the first controlled study in the world to investigate Ketamine-assisted therapy for the treatment of AUD and was published in the American Journal of Psychiatry in January. The study, conducted by the University of Exeter (UoE) and led by Prof. Celia Morgan, Professor of Psychopharmacology at UoE and Awakn’s Head of Ketamine-Assisted Therapy for addiction showed that ketamine and psychological therapy resulted in an 86% abstinence rate 6 months post treatment, an increase from 2% before the trial.

“This is another milestone in the advancement of successfully treating Alcohol Use Disorder,” said Awakn CMO Dr. Ben Sessa. “Currently there are millions suffering with very few promising lasting treatments and be it with MDMA or Ketamine-Assisted Therapy, we are exploring every promising avenue to treat a disease that not only impacts the individual, but also families and communities.”

NOTE

The safety and efficacy of MDMA-assisted therapy is currently under investigation. It has not yet been approved by medical regulators, does not work for everyone, and carries risks even in therapeutic settings. These statements are no guarantee of future regulatory approval or availability of MDMA-assisted therapy. These statements necessarily involve known and unknown risks and uncertainties, which may cause actual outcomes to differ materially from our projections.

About MAPS

Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since its founding, MAPS has raised over $130 million in donations and grants for psychedelic and marijuana research and education and has earned both the Guidestar Platinum Seal of Transparency and a 4-Star Rating from Charity Navigator. Learn more at maps.org.

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are advancing the next generation of psychedelic drugs and therapies to be used in combination.

 www.awaknlifesciences.com  |  Twitter  |  LinkedIn  |  Facebook

Notice Regarding Forward Looking Information

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company’s future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved the intended business of the Company, the expansion of the Company’s business, generation of revenue. All forward-looking statements, including those herein are qualified by this cautionary statement.

Investor Enquiries:

KCSA Strategic Communications 
Valter Pinto / Tim Regan 
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:

America and Canada: KCSA Strategic Communications  
Anne Donohoe 
Adonohoe@KCSA.com

Rest of World: ROAD Communications 
Paul Jarman / Anna Ramsey
Awakn@roadcommunications.co.uk